STAAR/$STAA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About STAAR
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Ticker
$STAA
Sector
Primary listing
Employees
1,157
Headquarters
Website
STAAR Metrics
BasicAdvanced
$1.4B
-
-$1.93
0.62
-
Price and volume
Market cap
$1.4B
Beta
0.62
52-week high
$36.24
52-week low
$13.50
Average daily volume
2.5M
Financial strength
Current ratio
4.943
Quick ratio
3.832
Long term debt to equity
10.523
Total debt to equity
12.039
Profitability
EBITDA (TTM)
-72.989
Gross margin (TTM)
71.70%
Net profit margin (TTM)
-42.45%
Operating margin (TTM)
-36.28%
Effective tax rate (TTM)
2.36%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-10.71%
Return on equity (TTM)
-25.55%
Valuation
Price to revenue (TTM)
6.097
Price to book
4.06
Price to tangible book (TTM)
4.38
Price to free cash flow (TTM)
-31.286
Free cash flow yield (TTM)
-3.20%
Free cash flow per share (TTM)
-0.887
Growth
Revenue change (TTM)
-32.59%
Earnings per share change (TTM)
-685.67%
3-year revenue growth (CAGR)
-4.98%
10-year revenue growth (CAGR)
12.02%
3-year earnings per share growth (CAGR)
40.97%
10-year earnings per share growth (CAGR)
23.26%
What the Analysts think about STAAR
Analyst ratings (Buy, Hold, Sell) for STAAR stock.
Bulls say / Bears say
Excluding China, Q2 2025 net sales rose 10% year-over-year to $39.0 million, demonstrating resilience and underlying demand in core markets (Reuters)
Q2 2025 net sales of $44.3 million beat analyst expectations by about 9%, underscoring the company’s ability to outperform consensus despite regional headwinds (Reuters)
The board authorized a $30 million share repurchase program in May 2025, reflecting management’s confidence in STAAR’s valuation and commitment to shareholder value (Investing.com)
Net sales plunged 55% year-over-year to $44.3 million in Q2 2025, primarily due to a planned reduction of channel inventory in China, highlighting the company’s vulnerability to its largest market (Reuters)
STAAR Surgical reported a net loss of $16.8 million in Q2 2025 versus a net income of $7.4 million in the prior-year period, reflecting deepening profitability challenges as China headwinds persist (Reuters)
Analysts’ median 12-month price target of $20.00 is about 35% below STAAR’s August 5 closing price of $27.02, suggesting limited upside from current levels (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
STAAR Financial Performance
Revenues and expenses
STAAR Earnings Performance
Company profitability
STAAR News
AllArticlesVideos
STAAR Surgical Reiterates Compelling, Premium Cash Value Provided by Alcon Merger
Business Wire·19 hours ago
Shareholder Alert: The Ademi Firm Investigates Whether STAAR Surgical Company Is Obtaining a Fair Price for Its Public Shareholders
Business Wire·4 weeks ago
STAAR SURGICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of STAAR Surgical Company - STAA
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for STAAR stock?
STAAR (STAA) has a market cap of $1.4B as of September 03, 2025.
What is the P/E ratio for STAAR stock?
The price to earnings (P/E) ratio for STAAR (STAA) stock is 0 as of September 03, 2025.
Does STAAR stock pay dividends?
No, STAAR (STAA) stock does not pay dividends to its shareholders as of September 03, 2025.
When is the next STAAR dividend payment date?
STAAR (STAA) stock does not pay dividends to its shareholders.
What is the beta indicator for STAAR?
STAAR (STAA) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.